Page last updated: 2024-11-07

opc 3911

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

OPC 3911: RN from CA Index Guide 1982-86 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID131164
SCHEMBL ID11062188
MeSH IDM0168882

Synonyms (11)

Synonym
butanamide, n-cyclohexyl-n-(2-hydroxyethyl)-4-((1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)oxy)-
opc 3911
76470-87-6
n-cyclohexyl-n-(2-hydroxyethyl)-4-[(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)oxy]butanamide
n-cyclohexyl-n-(2-hydroxyethyl)-4-[(2-oxo-3,4-dihydro-1h-quinolin-6-yl)oxy]butanamide
n-cyclohexyl-n-(2-hydroxyethyl)-4-((1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)oxy)butyramide
opc-3911
SCHEMBL11062188
OKVCJEKPURYZKG-UHFFFAOYSA-N
6-{3-[n-(2-hydroxyethyl)-n-cyclohexylaminocarbonyl]propoxy}-3,4-dihydrocarbostyril
DTXSID40997849

Research Excerpts

Overview

OPC 3911 is a potent inhibitor and PDE III is a specific inhibitor in cardiac muscle.

ExcerptReferenceRelevance
"OPC 3911 is a potent inhibitor and PDE III is a specific inhibitor in cardiac muscle. "( The inotropic mechanism of the phosphodiesterase inhibitor OPC 3911 alone and in combination with rolipram, studied in papillary muscles of ferret and guinea-pig and isolated myocytes of guinea-pig ventricular muscle.
Arlock, P; Lindgren, S; Mörner, SE, 1994
)
1.97

Compound-Compound Interactions

ExcerptReferenceRelevance
" The effects of the drug alone and in combination with the non-inotropic PDE IV inhibitor rolipram were analysed using hearts from guinea-pigs and ferrets."( The inotropic mechanism of the phosphodiesterase inhibitor OPC 3911 alone and in combination with rolipram, studied in papillary muscles of ferret and guinea-pig and isolated myocytes of guinea-pig ventricular muscle.
Arlock, P; Lindgren, S; Mörner, SE, 1994
)
0.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (6.25)18.7374
1990's11 (68.75)18.2507
2000's4 (25.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.57 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index5.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]